Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

The chemistry of nitrogen-containing heterocyclic compound pyrrole and pyrrolidine has
been a versatile field of study for a long time for its diverse biological and medicinal …

Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into
the proximity of proteins of interest, inducing ubiquitination-dependent degradation. A major …

Neurodegenerative diseases (NDs) are currently incurable diseases that cause progressive
degeneration of nerve cells. Many of the disease-causing proteins of NDs are “undruggable” …

Protein degradation technology has progressed dramatically since 2001 when proteolysis
targeting chimera (PROTAC) was first reported. Various of distinctive degradation …

Ubiquitination is a posttranslational modification that regulates a multitude of cellular
functions. Pathogens, such as bacteria and viruses, have evolved sophisticated …